Concord Biotech sets November 4 record for 1:1 bonus shares
The Ahmedabad-based biopharmaceutical firm's stock closed 1.25% higher on October 30, despite a 14.28% decline over the past year.
Bonus Share Issue Details
Concord Biotech, the Ahmedabad-headquartered biopharmaceutical manufacturer, has confirmed November 4 as the record date for its 1:1 bonus share issue. This corporate action means eligible shareholders will receive one additional equity share for every fully paid-up share they currently hold. To qualify, investors must possess the company's shares by November 3.
The issuance of these new shares remains contingent on securing all necessary statutory and regulatory approvals. According to data from the BSE website as of November 1, this is the sole bonus issue record date scheduled for the upcoming week.
Recent Market Performance
Shares of Concord Biotech concluded trading on October 30 at ₹1,245.30 on the BSE, marking a 1.25% increase for the day. This closing price contributed to the company's market capitalisation of ₹13,027.86 crore. The stock has shown a 1.34% return over the past week.
However, its performance has been mixed in the short term, experiencing a 6.97% decline over the last two weeks and a 9.33% drop in the past month, according to market data.
Longer-Term Trends and IPO Context
Despite recent gains, Concord Biotech's share price has fallen approximately 14.28% over the past year. The stock reached its 52-week high of ₹1,614.05 on August 20, 2026, and its 52-week low of ₹987.05 on April 2, 2026. The company initially listed on exchanges in August 2023 with an issue price of ₹741 per share.
Since its initial public offering (IPO), the stock has delivered a return of nearly 68% for investors, demonstrating significant growth from its listing price.
For investors in Concord Biotech, the upcoming bonus issue on November 4 will adjust the number of shares held without immediately altering the overall value of their investment. The immediate focus will be on the stock's price behaviour as it trades ex-bonus, typically seeing a proportionate decrease.
Shareholders should also monitor the progress of the statutory and regulatory approvals, which are prerequisites for the actual distribution of the bonus shares. The company's relative outperformance since its 2023 IPO, contrasted with its recent annual decline, highlights the importance of observing sector-wide sentiment within India's pharmaceutical market.
This article is journalism, not investment advice; consult a licensed professional before making financial decisions. Market data is indicative, may be delayed, and should be verified with your broker or exchange before use.
Comments.
Comments are moderated. We remove what is unlawful, abusive or off-topic, and and you remain responsible for what you post.
Reader comments open soon. Until then, corrections and responses go to our newsroom, and we publish what we get wrong on Corrections.